28399-31-7 Usage
Description
DCP-LA, also known as FR 236924, is a compound that acts as a PKCε activator. It has been identified for its potential therapeutic applications in the treatment of Alzheimer's disease, as it targets the lowered PKCε activator levels associated with Aβ degradation, a key characteristic of the disease.
Uses
Used in Pharmaceutical Industry:
DCP-LA is used as a therapeutic agent for the treatment of Alzheimer's disease. DCP-LA acts as a PKCε activator, which is linked to Aβ degradation, a hallmark of Alzheimer's disease. By increasing PKCε activator levels, DCP-LA may help in the degradation of Aβ and provide therapeutic benefits for Alzheimer's patients.
Additionally, if there are other applications or industries where DCP-LA is used, they can be listed in a similar format as follows:
Used in [Application Industry]:
DCP-LA is used as [application type] for [application reason].
Biological Activity
fr 236924 is a selective activator of pkc-ε [1].pkc is a monomeric ca2+- and phospholipid-dependent ser/thr protein kinase and plays an important role in growth factor-activated signaling and malignant transformation.fr 236924 (dcp-la) is a selective pkc-ε activator. in pc-12 cells, dcp-la (10 nm-100 μm) activated pkc in a concentration dependent way with the maximal effect at 100 nm. in the cell-free system, dcp-la (100 μm) significantly activated pkc-ε and exhibited >7-fold potency over other pkc isozymes (α,βi, βii, γ, δ, μ, η and ζ), suggesting that dcp-la was a selective pkc-ε activator. dcp-la exhibited the maximal effect on pkc-ε at 100 μm. the activation of pkc-ε induced by dcp-la (100 μm) was inhibited by dioleoyl-phosphatidylserine in a concentration dependent way, suggesting that dcp-la might bound to the phosphatidylserine binding site on pkc-ε. however, dioleoyl-phosphatidylserine increased dcp-la (100 μm)-induced pkc-ε activation in a concentration dependent way, suggesting a different activation mechanism [1]. in xenopus oocytes expressing α7 receptors, fr236924 (10 μm) induced a persistent increased α7 receptor responses to 144% via a pkc pathway. in rat hippocampal slices, fr236924 (10 nm to 10 μm) facilitated hippocampal neurotransmission [2].in the hippocampus of rats, fr236924 induced glutamate release and facilitated hippocampal synaptic transmission through pkc [3].
Biochem/physiol Actions
DCP-LA is a selective PKC-epsilon (PKC-ε) activator. In the in situ PKC assay with a reversed phase high-performance liquid chromatography, DCP-LA significantly activated PKC in PC-12 cells in a concentration (10 nM-100 μM)-dependent manner, with the maximal effect at 100 nM. DCP-LA has over a 7-fold greater potency for activation of PKC-ε over other PKC isozymes.
references
[1]. kanno t, yamamoto h, yaguchi t, et al. the linoleic acid derivative dcp-la selectively activates pkc-epsilon, possibly binding to the phosphatidylserine binding site. j lipid res, 2006, 47(6): 1146-1156. [2]. tanaka a, nishizaki t. the newly synthesized linoleic acid derivative fr236924 induces a long-lasting facilitation of hippocampal neurotransmission by targeting nicotinic acetylcholine receptors. bioorg med chem lett, 2003, 13(6): 1037-1040.[3]. yamamoto s, kanno t, nagata t, et al. the linoleic acid derivative fr236924 facilitates hippocampal synaptic transmission by enhancing activity of presynaptic alpha7 acetylcholine receptors on the glutamatergic terminals. neuroscience, 2005, 130(1): 207-213.
Check Digit Verification of cas no
The CAS Registry Mumber 28399-31-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,8,3,9 and 9 respectively; the second part has 2 digits, 3 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 28399-31:
(7*2)+(6*8)+(5*3)+(4*9)+(3*9)+(2*3)+(1*1)=147
147 % 10 = 7
So 28399-31-7 is a valid CAS Registry Number.
InChI:InChI=1/C20H36O2/c1-2-3-7-10-16-13-18(16)15-19-14-17(19)11-8-5-4-6-9-12-20(21)22/h16-19H,2-15H2,1H3,(H,21,22)
